December 2024
PrIMAVeRa is proud to be part of the IMI Antimicrobial Resistance (AMR) Accelerator, an Innovative Medicines Initiative (IMI) program comprising nine projects united in their mission to advance the development of new medicines to treat or prevent resistant bacterial infections. In its latest newsletter, the AMR Accelerator highlighted PrIMAVeRa’s achievements and ongoing contributions to this critical effort.
PrIMAVeRa supports the global fight against antimicrobial resistance (AMR) by developing a decision-making tool that integrates an epidemiological repository with mathematical models to prioritise vaccines and monoclonal antibodies (mAbs).
Highlights from PrIMAVeRa:
• Achievements: A recent publication on a Delphi expert consensus exercise conducted by the consortium underscores the challenges of accessing European data on AMR burden, emphasizing the urgent need for cross-sector collaboration to drive data-informed policies.
• Meet Our Researchers: Insights from early-career scientists driving innovation in AMR research:
o Targeting Supercontactors for Safer Long-Term Care: Read more
o A Doctor’s Mission to Stop Superbugs: Read more
• Key Publications: Recent studies, including systematic reviews and modelling research, provide critical insights into AMR research priorities and effective intervention strategies.
For more updates and events, check out the full AMR Accelerator newsletter here.
Together, we can drive innovation and develop effective solutions to tackle AMR and safeguard global health.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
Comentarios